Cerestat: Began a placebo-controlled safety trial using fixed doses instead of doses based on patients' weight, to run concomitantly with an on-going Phase II d

Cambridge Neuroscience Inc. (CNSI), Cambridge, Mass. Product: Cerestat, an NMDA channel blocker which prevents excess calcium entry into nerve cells Indication: Stroke Status: Began a placebo-controll...